胰腺癌治疗的最新进展。
Recent advances in the treatment of pancreatic cancer.
作者信息
Roth Marc T, Cardin Dana B, Berlin Jordan D
机构信息
Department of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
出版信息
F1000Res. 2020 Feb 21;9. doi: 10.12688/f1000research.21981.1. eCollection 2020.
Abstract
Pancreatic ductal adenocarcinoma is one of the deadliest solid tumor malignancies and is projected to become a leading cause of cancer-related death in coming years. Improving quality of life and survival amongst these patients will require new ideas and novel therapies in a multidisciplinary approach. This review will cover the most recent advances in the comprehensive treatment of pancreatic cancer and place them within a historical context when necessary. Treatment of all disease stages will be discussed, but the focus is on systemic therapy as novel drugs and new treatment combinations enter the clinic. This will include more aggressive chemotherapy in earlier disease stages, approved uses for immunotherapy, and targetable mutations. In addition, negative trials of importance and controversial topics will be noted.
摘要
胰腺导管腺癌是最致命的实体瘤恶性肿瘤之一，预计在未来几年将成为癌症相关死亡的主要原因。要提高这些患者的生活质量和生存率，需要采用多学科方法提出新想法和开展新疗法。本综述将涵盖胰腺癌综合治疗的最新进展，并在必要时将其置于历史背景中。将讨论所有疾病阶段的治疗，但重点是随着新型药物和新的治疗组合进入临床，系统性治疗。这将包括在疾病早期阶段采用更积极的化疗、免疫疗法的获批用途以及可靶向的突变。此外，还将提及重要的阴性试验和有争议的话题。
相似文献
1
Recent advances in the treatment of pancreatic cancer.胰腺癌治疗的最新进展。
F1000Res. 2020 Feb 21;9. doi: 10.12688/f1000research.21981.1. eCollection 2020.
2
Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes.胰腺癌：临床诊断、流行病学、治疗和结局的综述。
World J Gastroenterol. 2018 Nov 21;24(43):4846-4861. doi: 10.3748/wjg.v24.i43.4846.
3
Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma.胰腺导管腺癌的新辅助多模式治疗
Crit Rev Oncol Hematol. 2016 Feb;98:309-24. doi: 10.1016/j.critrevonc.2015.11.016. Epub 2015 Nov 23.
4
Perspectives in the treatment of pancreatic adenocarcinoma.胰腺腺癌的治疗前景
World J Gastroenterol. 2015 Aug 21;21(31):9297-316. doi: 10.3748/wjg.v21.i31.9297.
5
Update on the management of pancreatic cancer: surgery is not enough.胰腺癌管理的最新进展：手术并不够。
World J Gastroenterol. 2015 Mar 21;21(11):3157-65. doi: 10.3748/wjg.v21.i11.3157.
6
Multimodal treatment of resectable pancreatic ductal adenocarcinoma.可切除胰腺导管腺癌的多模式治疗。
Crit Rev Oncol Hematol. 2017 Mar;111:152-165. doi: 10.1016/j.critrevonc.2017.01.015. Epub 2017 Feb 4.
7
Neo-adjuvant therapy for pancreatic cancer: hope for the future.新辅助治疗胰腺癌：未来的希望。
Expert Rev Gastroenterol Hepatol. 2019 Jun;13(6):579-589. doi: 10.1080/17474124.2019.1607294. Epub 2019 May 2.
8
Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma.新辅助治疗交界性和可切除胰腺导管腺癌。
Clin Transl Oncol. 2017 Oct;19(10):1193-1198. doi: 10.1007/s12094-017-1680-8. Epub 2017 Jun 13.
9
Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma.局部晚期胰腺导管腺癌的治疗
Dig Surg. 2016;33(4):343-50. doi: 10.1159/000445020. Epub 2016 May 25.
10
Nodal downstaging as a treatment goal for node-positive pancreatic cancer.将淋巴结降期作为治疗目标治疗阳性胰腺癌。
Surgery. 2019 Jun;165(6):1144-1150. doi: 10.1016/j.surg.2018.12.009. Epub 2019 Feb 10.
引用本文的文献
1
Pharmacological inhibition of hypoxia induced acidosis employing a CAIX inhibitor sensitizes gemcitabine resistant PDAC cells.使用碳酸酐酶IX（CAIX）抑制剂对缺氧诱导的酸中毒进行药理学抑制可使吉西他滨耐药的胰腺导管腺癌（PDAC）细胞致敏。
Sci Rep. 2025 May 14;15(1):16782. doi: 10.1038/s41598-025-93388-5.
2
Proteome-Wide Investigation of Proline Hydroxylation in Pancreatic Ductal Adenocarcinoma Using DiLeu Isobaric Labeling Strategy.使用双亮氨酸等压标记策略对胰腺导管腺癌中脯氨酸羟化进行全蛋白质组研究。
Mol Cell Proteomics. 2025 Apr 9;24(7):100969. doi: 10.1016/j.mcpro.2025.100969.
3
METTL3-dependent m6A methylation of circCEACAM5 fuels pancreatic cancer progression through DKC1 activation.METTL3依赖的环状CEACAM5的m6A甲基化通过激活DKC1促进胰腺癌进展。
Cell Mol Life Sci. 2025 Mar 27;82(1):132. doi: 10.1007/s00018-025-05653-5.
4
Radiopharmaceuticals for Pancreatic Cancer: A Review of Current Approaches and Future Directions.用于胰腺癌的放射性药物：当前方法与未来方向综述
Pharmaceuticals (Basel). 2024 Oct 1;17(10):1314. doi: 10.3390/ph17101314.
5
The roles of lncRNAs and miRNAs in pancreatic cancer: a focus on cancer development and progression and their roles as potential biomarkers.长链非编码RNA和微小RNA在胰腺癌中的作用：聚焦于癌症的发生发展及其作为潜在生物标志物的作用
Front Oncol. 2024 Mar 15;14:1355064. doi: 10.3389/fonc.2024.1355064. eCollection 2024.
6
Redox proteomics of PANC-1 cells reveals the significance of HIF-1 signaling protein oxidation in pancreatic ductal adenocarcinoma pathogenesis.PANC-1 细胞的氧化还原蛋白质组学揭示了 HIF-1 信号蛋白氧化在胰腺导管腺癌发病机制中的重要性。
J Transl Med. 2024 Mar 16;22(1):287. doi: 10.1186/s12967-024-05068-z.
7
Bulk anda single-cell transcriptome profiling reveals the molecular characteristics of T cell-mediated tumor killing in pancreatic cancer.批量和单细胞转录组分析揭示了胰腺癌中T细胞介导的肿瘤杀伤的分子特征。
Heliyon. 2024 Feb 28;10(5):e27216. doi: 10.1016/j.heliyon.2024.e27216. eCollection 2024 Mar 15.
8
High Level of Adropin Promotes the Progression of Pancreatic Ductal Adenocarcinoma.Adropin 水平升高促进胰腺导管腺癌的进展。
Curr Cancer Drug Targets. 2024;24(6):629-641. doi: 10.2174/0115680096267203231024093601.
9
Critical Role of Novel O-GlcNAcylation of S550 and S551 on the p65 Subunit of NF-κB in Pancreatic Cancer.新型O-连接N-乙酰葡糖胺糖基化修饰S550和S551对胰腺癌中NF-κB的p65亚基的关键作用
Cancers (Basel). 2023 Sep 27;15(19):4742. doi: 10.3390/cancers15194742.
10
A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas.帕博西尼联合 Nab-紫杉醇治疗转移性胰腺腺癌的临床前和 Ib 期研究。
Cancer Res Commun. 2022 Nov 2;2(11):1326-1333. doi: 10.1158/2767-9764.CRC-22-0072. eCollection 2022 Nov.
本文引用的文献
1
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.帕博利珠单抗治疗非结直肠癌高度微卫星不稳定/错配修复缺陷型癌症患者的疗效：来自 II 期 KEYNOTE-158 研究的结果。
J Clin Oncol. 2020 Jan 1;38(1):1-10. doi: 10.1200/JCO.19.02105. Epub 2019 Nov 4.
2
Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer: A Phase 1b/2 Pilot Clinical Trial.白蛋白结合型紫杉醇联合吉西他滨和顺铂治疗晚期胰腺癌患者后的缓解率：一项1b/2期先导性临床试验
JAMA Oncol. 2020 Jan 1;6(1):125-132. doi: 10.1001/jamaoncol.2019.3394.
3
Strategies in Developing Immunotherapy for Pancreatic Cancer: Recognizing and Correcting Multiple Immune "Defects" in the Tumor Microenvironment.胰腺癌免疫治疗的发展策略：识别并纠正肿瘤微环境中的多种免疫“缺陷”
J Clin Med. 2019 Sep 16;8(9):1472. doi: 10.3390/jcm8091472.
4
Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline.放射治疗胰腺癌：ASTRO 临床实践指南执行摘要。
Pract Radiat Oncol. 2019 Sep-Oct;9(5):322-332. doi: 10.1016/j.prro.2019.06.016.
5
Checkpoint inhibitors in pancreatic cancer.胰腺癌的检查点抑制剂。
Cancer Treat Rev. 2019 Aug;78:17-30. doi: 10.1016/j.ctrv.2019.06.005. Epub 2019 Jun 27.
6
Maintenance Olaparib for Germline -Mutated Metastatic Pancreatic Cancer.维持奥拉帕利治疗种系突变转移性胰腺癌。
N Engl J Med. 2019 Jul 25;381(4):317-327. doi: 10.1056/NEJMoa1903387. Epub 2019 Jun 2.
7
NCCN Guidelines Updates: Pancreatic Cancer.NCCN 指南更新：胰腺癌。
J Natl Compr Canc Netw. 2019 May 1;17(5.5):603-605. doi: 10.6004/jnccn.2019.5007.
8
Cancer statistics, 2019.癌症统计数据，2019 年。
CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.
9
Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05).吉西他滨与S-1新辅助化疗对比直接手术治疗可切除胰腺癌的随机II/III期试验（Prep-02/JSAP05）
Jpn J Clin Oncol. 2019 Feb 1;49(2):190-194. doi: 10.1093/jjco/hyy190.
10
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.FOLFIRINOX 或吉西他滨作为胰腺癌的辅助治疗。
N Engl J Med. 2018 Dec 20;379(25):2395-2406. doi: 10.1056/NEJMoa1809775.
Zotero 插件